Biocircuits: Market Realities, Technology Commitments
Executive Summary
Biocircuits was failing along with its breakthrough diagnostics invention until it saw that its raison d’etre was a marketplace, not a technology. That understanding allowed it to see other ways to make its projects into commercial realities. Instead of risking its remaining money on perfecting its breakthrough but intractable technology, it has switched to working on a product based on traditional technology. But Biocircuits' delays have cost it a major market opportunity and forced it to confront, at product launch, a marketplace in the process of radical transformation.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.